Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Adam

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
International Journal of Molecular Sciences|August 7, 2021
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical PerspectiveCristina Hernando, Belén Ortega-Morillo, Marta Tapia, et al.
ACS Applied Materials & Interfaces|August 7, 2023
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer TherapyIris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, et al.
Scientific Reports|March 31, 2019
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factorsEduardo Tormo, Sandra Ballester, Anna Adam-Artigues, et al.
ACS Infectious Diseases|November 3, 2024
Global Health Priority Box─Proactive Pandemic PreparednessAnna Adam, Dominique Besson, Rob Bryant, et al.
International Journal of Molecular Sciences|October 14, 2020
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast CancerIris Garrido-Cano, Vera Constâncio, Anna Adam-Artigues, et al.
Cancer Communications (London, England)|August 23, 2022
miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studiesIris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, et al.
ACS Infectious Diseases|March 14, 2022
The Pandemic Response Box─Accelerating Drug Discovery Efforts after Disease OutbreaksKirandeep Samby, Dominique Besson, Anirban Dutta, et al.
Frontiers in Oncology|October 5, 2020
MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast CarcinomaBirlipta Pattanayak, Iris Garrido-Cano, Anna Adam-Artigues, et al.
Cancers|April 13, 2023
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast CancerPaula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues, et al.
Cancers|July 2, 2021
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast CancerAnna Adam-Artigues, Iris Garrido-Cano, Juan Antonio Carbonell-Asins, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|August 7, 2021
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical PerspectiveCristina Hernando, Belén Ortega-Morillo, Marta Tapia, et al.
ACS Applied Materials & Interfaces|August 7, 2023
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer TherapyIris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, et al.
Scientific Reports|March 31, 2019
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factorsEduardo Tormo, Sandra Ballester, Anna Adam-Artigues, et al.
ACS Infectious Diseases|November 3, 2024
Global Health Priority Box─Proactive Pandemic PreparednessAnna Adam, Dominique Besson, Rob Bryant, et al.
International Journal of Molecular Sciences|October 14, 2020
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast CancerIris Garrido-Cano, Vera Constâncio, Anna Adam-Artigues, et al.
Cancer Communications (London, England)|August 23, 2022
miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studiesIris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, et al.
ACS Infectious Diseases|March 14, 2022
The Pandemic Response Box─Accelerating Drug Discovery Efforts after Disease OutbreaksKirandeep Samby, Dominique Besson, Anirban Dutta, et al.
Frontiers in Oncology|October 5, 2020
MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast CarcinomaBirlipta Pattanayak, Iris Garrido-Cano, Anna Adam-Artigues, et al.
Cancers|April 13, 2023
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast CancerPaula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues, et al.
Cancers|July 2, 2021
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast CancerAnna Adam-Artigues, Iris Garrido-Cano, Juan Antonio Carbonell-Asins, et al.
Pageof 3